Sox2 maintains self-renewal of tumor initiating cells in osteosarcomas

DSpace/Manakin Repository

Sox2 maintains self-renewal of tumor initiating cells in osteosarcomas

Citable link to this page

 

 
Title: Sox2 maintains self-renewal of tumor initiating cells in osteosarcomas
Author: Basu-Roy, Upal; Seo, Eunjeong; Ramanathapuram, Lalitha; Rapp, Timothy B.; Perry, Jennifer; Orkin, Stuart Holland; Mansukhani, Alka; Basilico, Claudio

Note: Order does not necessarily reflect citation order of authors.

Citation: Basu-Roy, Upal, Eunjeong Seo, Lalitha Ramanathapuram, Timothy B. Rapp, Jennifer A. Perry, Stuart H. Orkin, Alka Mansukhani, and Claudio Basilico. 2011. Sox2 maintains self-renewal of tumor initiating cells in osteosarcomas. Oncogene 31(18): 2270-2282.
Full Text & Related Files:
Abstract: Tumors are thought to be sustained by a reservoir of self-renewing cells, termed tumor initiating cells or cancer stem cells. Osteosarcomas are high-grade sarcomas derived from osteoblast progenitor cells and are the most common pediatric bone malignancy. In this report we show that the stem cell transcription factor Sox2 is highly expressed in human and murine osteosarcoma cell lines as well as in tumor samples. Osteosarcoma cells have increased ability to grow in suspension as osteospheres, that are greatly enriched in expression of Sox2 and the stem cell marker, Sca-1. Depletion of Sox2 by shRNAs in independent murine osteosarcoma-derived cells drastically reduces their transformed properties in vitro and their ability to form tumors. Sox2-depleted osteosarcoma cells can no longer form osteospheres, and differentiate into mature osteoblasts. Concomitantly, they exhibit decreased Sca-1 expression and upregulation of the Wnt signaling pathway. Thus, despite other mutations, these tumor cells maintain a proliferative requirement for Sox2. Our data indicate that Sox2 is required for osteosarcoma cell self-renewal, and that Sox2 antagonizes the pro-differentiation Wnt pathway, that can in turn reduce Sox2 expression. These studies define Sox2 as a survival factor and a novel biomarker of self-renewal in osteosarcomas, and support a tumor suppressive role for the Wnt pathway in tumors of mesenchymal origin. Our findings could provide the basis for novel therapeutic strategies based on inhibiting Sox2 or enhancing Wnt signaling for the treatment of osteosarcomas.
Published Version: doi:10.1038/onc.2011.405
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243769/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10579096
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters